Longevity Life Sciences named finalist in the 2026 NutraIngredients-Asia Awards
LLS has been shortlisted for the Start-Up Award from a record field of entries across the Asia-Pacific nutrition industry.
Longevity Life Sciences has been named a finalist in the Start-Up Award category of the 2026 NutraIngredients-Asia Awards.
The official 2026 finalist announcement confirms LLS as one of three finalists in the category, alongside HiveEnergy Sports Gel and Taama.
The 2026 awards attracted a record 256 entries, more than 30% above the previous year, according to NutraIngredients-Asia.
The recognition follows a significant period of development for LLS.
Since establishing the CellVive® platform, the company has helped establish a regulated pathway for NMN in Australia, supported the commercial introduction of CellVive NMN®, entered a multi-year strategic research partnership with the University of Sydney and expanded its international biotechnology and formulation partnerships.
LLS is now developing a broader portfolio of cellular-health technologies through collaborations spanning research, advanced manufacturing, formulation and ingredient innovation.
The finalist recognition reflects the company’s ambition to build an Australian life-sciences platform focused on a central challenge: how promising advances in cellular biology can be translated into evidence-led, regulated and commercially scalable health solutions.
The winner will be announced at the NutraIngredients-Asia Awards presentation in September 2026.
